The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Imviva Biotech's CTD402 to accelerate the ...
The autoimmune diagnostic company expects its new assay to be available by the end of this year or in early 2027.
Investing.com - Canaccord Genuity has reiterated its Buy rating and $15.00 price target on Exagen (NASDAQ:XGN) following the company’s preliminary fourth-quarter 2025 results announcement. The $15 ...
Delhi IRL gets central certification to test key drugs for drug-resistant TB 13 Jan 2026 \| 12:03 AM. Pankaj Jain New Delhi, Jan 12 (UNI) Delhi’s Intermediate Reference Laborator ...
The MarketWatch News Department was not involved in the creation of this content. CARLSBAD, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune ...
Record full year 2025 revenue, an increase of at least 19% over 2024 AVISE CTD trailing 12-month (TTM) ASP expansion by at least $30 compared to 2024 AVISE CTD test volume growth of at least 13,000, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results